Literature DB >> 2406324

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule.

A Hejjaoui1, H Dhivert, F B Michel, J Bousquet.   

Abstract

Specific immunotherapy with standardized extracts can induce systemic reactions (SRs), possibly increased by a rush immunotherapy (RIT) protocol. A prospective study in 1152 mite-allergic patients (3 to 63 years of age) examined the incidence of SRs during an RIT or a step protocol. All patients received the same standardized extract of Dermatophagoides pteronyssinus with the same maintenance dose. In the first group, 290 patients had an RIT protocol without any preventive measure. In a second group, the prevention of SRs during RIT was attempted by pretreating 160 patients with methylprednisolone (0.5 mg/kg/day), ketotifen (2 mg/day), and theophylline (10 mg/kg/day). In a third group (479 patients), the same pretreatment was associated with preventive measures and with FEV1 results and the occurrence of large local reactions. A fourth group consisted of 223 patients who received a step protocol with the same pretreatment and preventive measures. The incidence of SRs per patient was 36.2% with RIT alone, 16.2% when the pretreatment was added, and 7.2% when pretreatment and preventive measures were used. Patients receiving the step protocol had 5.4% SRs. Adrenaline had to be used from 10.0%, 4.6%, 0.2%, and 0.2%, respectively. No reaction started 45 minutes or later after the last injection. Children younger than 5 years of age had a significantly greater number of SR.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406324     DOI: 10.1016/0091-6749(90)90157-y

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

Review 1.  Allergic emergencies in the physician's office.

Authors:  P A Greenberger
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Allergen immunotherapy.

Authors:  R E Esch; J Portnoy
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

Review 3.  Immunotherapy in asthma.

Authors:  J A Douglass; F C Thien; R E O'Hehir
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

4.  Safety and efficacy of rush allergen-specific immunotherapy in Chinese allergic rhinitis patients.

Authors:  Qianhui Qiu; Mimi Xu; Chuan Lu; Jianjun Chen; Shaohua Chen; Weijia Kong; Hong Han
Journal:  Int J Immunopathol Pharmacol       Date:  2016-08-10       Impact factor: 3.219

Review 5.  Specific immunotherapy in house dust mite allergy.

Authors:  J Bousquet; A Des Roches; L Paradis; H Dhivert; F B Michel
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 6.  Minimising the risks of allergen-specific injection immunotherapy.

Authors:  H J Malling
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

7.  Hyposensitization to allergic reaction in rDer f 2-sensitized mice by the intranasal administration of a mutant of rDer f 2, C8/119S.

Authors:  M Yasue; T Yokota; M Fukada; T Takai; M Suko; H Okudaira; Y Okumura
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 8.  Accelerated immunotherapy schedules.

Authors:  Christopher W Calabria
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 9.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 10.  Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party.

Authors:  A J Frew
Journal:  BMJ       Date:  1993-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.